ImmBio is developing next-generation vaccines targeting a number of serious infectious diseases, based on its proprietary technologies.
Business Model:
Revenue: $0
Employees: 51-200
Address:
City: Cambridge
State: Cambridgeshire
Zip:
Country: United Kingdom
ImmBio is developing next-generation vaccines targeting a number of serious infectious diseases, based on its proprietary technologies. ImmBio is developing next-generation vaccines against serious infectious disease targets, utilising its proprietary technology platforms to directly induce immunity via dendritic cells. ImmBio&s;s lead programme is a vaccine against invasive pneumococcal disease, PnuBioVax™, that has recently progressed into full clinical development with the successful completion of a Phase I Clinical trial.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 12/2000 | Seed Round | 1 | - |
Oxford Technology Management Oxford Technology Management |
11/2005 | Venture Round | 1 | - |
Hygea VCT Hygea VCT |
3/2013 | Grant | $297.9k | 10/2012 | Venture Round | 1 | $4.8M |
YFM Equity Partners YFM Equity Partners |
11/2005 | Venture Round | 1 | - |
Hygea VCT Hygea VCT |
12/2000 | Seed Round | 1 | - |
Oxford Technology Management Oxford Technology Management |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|